To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis

References

• Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007;184(1-2):37–44.
   PubMed Web of Science ®Google Scholar
• Gelfand JM. Chapter 12 - Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. In: Goodin DS, editor. Handbook of clinical neurology. Vol. 122. Elsevier; 2014. p. 269–290.
   Google Scholar
• Multiple Sclerosis Trust – How common is multiple sclerosis? 2022. https://mstrust.org.uk/a-z/how-common-multiple-sclerosis
   Google Scholar
• Multiple Sclerosis Trust. Types of MS. Relapsing remitting MS (RRMS). 2022. https://www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms
   Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314–324.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis. Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Simonsen CS, Flemmen HØ, Broch L, et al. The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. J Neurol. 2021;268(4):1330–1341.
   PubMed Web of Science ®Google Scholar
• Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(7):1900–1913.
   PubMedGoogle Scholar
• Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–2015.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–1438.
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Thygesen LC, Sørensen PS, et al. Worsening of disability caused by relapses in multiple sclerosis: a different approach. Mult Scler Relat Disord. 2019;32:1–8.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528–1532.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914–1929.
   PubMedGoogle Scholar
• Scott TF, Diehl D, Elmalik W, et al. Multiple sclerosis relapses contribute to long-term disability. Acta Neurol Scand. 2019;140(5):336–341.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147–3161.
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Trust. Disease modifying therapies. 2022. https://www.mssociety.org.uk/about-ms/treatments-and-therapies/disease-modifying-therapies.
   Google Scholar
• Scolding N, Barnes D, Cader S, et al. Association of british neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–279.
   PubMedGoogle Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495–507.
   PubMed Web of Science ®Google Scholar
• Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041–e1051.
   PubMed Web of Science ®Google Scholar
• He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–316.
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Butzkueven H, et al. Early treatment delays long-term disability accrual in RRMS: results from the BMSD network. Mult Scler. 2021;27(10):1543–1555.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Ofatumumab for treating relapsing multiple sclerosis (TA699). 2021. https://www.nice.org.uk/guidance/ta699.
   Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, ASCLEPIOS I and ASCLEPIOS II Trial Groups, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557.
   PubMed Web of Science ®Google Scholar
• Bottomley C, Lloyd A, Bennett G, et al. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in multiple sclerosis. J Med Econ. 2017;20(8):863–870.
   PubMed Web of Science ®Google Scholar
• Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263–275.
   PubMed Web of Science ®Google Scholar
• Montgomery SM, Kusel J, Nicholas R, et al. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. J Med Econ. 2017;20(9):962–973.
   PubMed Web of Science ®Google Scholar
• Montgomery SM, Maruszczak MJ, Slater D, et al. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. J Med Econ. 2017;20(5):474–482.
   PubMed Web of Science ®Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101–106.
   PubMedGoogle Scholar
• Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies (NHS England Reference: 170079ALG). 2019. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Siponimod for treating secondary progressive multiple sclerosis (TA656). 2020. https://www.nice.org.uk/guidance/ta656
   Google Scholar
• Kappos L, Bar-Or A, Cree BAC, EXPAND Clinical Investigators, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273.
   PubMed Web of Science ®Google Scholar
• Schur N, Gudala K, Vudumula U, et al. Cost effectiveness and budget impact of siponimod compared to interferon beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland. Pharmacoeconomics. 2021;39(5):563–577.
   PubMed Web of Science ®Google Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255–1274.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527). 2018. https://www.nice.org.uk/guidance/ta527
   Google Scholar
• National Institute for Health and Care Excellence. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127). 2007. https://www.nice.org.uk/guidance/ta127
   Google Scholar
• Jones KH, Jones PA, Middleton RM, et al. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS register. PLoS One. 2014;9(8):e104604.
   PubMed Web of Science ®Google Scholar
• Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26(1):109–119.
   PubMed Web of Science ®Google Scholar
• Yildiz M. The impact of slower walking speed on activities of daily living in patients with multiple sclerosis. Int J Clin Pract. 2012;66(11):1088–1094.
   PubMed Web of Science ®Google Scholar
• Bauer B, Brockmeier B, Devonshire V, et al. An international discrete choice experiment assessing patients’ preferences for disease-modifying therapy attributes in multiple sclerosis. Neurodegener Dis Manag. 2020;10(6):369–382.
   PubMed Web of Science ®Google Scholar
• Noon KM, Montgomery SM, Adlard NE, et al. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis. J Med Econ. 2018;21(10):983–992.
   PubMed Web of Science ®Google Scholar
• The NHS Long Term Plan. 2019. https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf
   Google Scholar